The stock of Biosyent Inc. (CVE:RX) is a huge mover today! About 7,647 shares traded hands. Biosyent Inc. (CVE:RX) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 5 months negative chart setup for the $114.95M company. It was reported on Nov, 28 by Barchart.com. We have $7.44 PT which if reached, will make CVE:RX worth $8.05 million less.
More news for Biosyent Inc. (CVE:RX) were recently published by: Midasletter.com, which released: “Small Cap Discoveries Editor Paul Andreola on Lingo Media Corp, Biosyent Inc …” on January 19, 2016. Marketwired.com‘s article titled: “BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular …” and published on May 25, 2016 is yet another important article.
BioSyent Inc. is a specialty pharmaceutical company. The company has a market cap of $114.95 million. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has a 29.17 P/E ratio. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.